244.79
전일 마감가:
$245.12
열려 있는:
$244.5
하루 거래량:
1.06M
Relative Volume:
1.02
시가총액:
$35.89B
수익:
$5.02B
순이익/손실:
$1.31B
주가수익비율:
27.47
EPS:
8.91
순현금흐름:
$1.56B
1주 성능:
+0.80%
1개월 성능:
+2.97%
6개월 성능:
-1.70%
1년 성능:
+16.93%
Resmed Inc Stock (RMD) Company Profile
명칭
Resmed Inc
전화
(858) 746-2400
주소
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
RMD을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
RMD
Resmed Inc
|
244.79 | 35.61B | 5.02B | 1.31B | 1.56B | 8.91 |
![]()
ISRG
Intuitive Surgical Inc
|
552.34 | 193.38B | 8.71B | 2.48B | 1.75B | 6.82 |
![]()
BDX
Becton Dickinson Co
|
172.59 | 49.12B | 20.87B | 1.50B | 2.59B | 5.24 |
![]()
ALC
Alcon Inc
|
85.94 | 42.79B | 9.93B | 1.12B | 1.58B | 2.25 |
![]()
BAX
Baxter International Inc
|
30.50 | 15.46B | 11.89B | -560.00M | 191.00M | -1.10 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-03-19 | 개시 | Morgan Stanley | Overweight |
2025-01-16 | 개시 | Goldman | Buy |
2025-01-10 | 개시 | Piper Sandler | Neutral |
2024-12-13 | 개시 | Stifel | Hold |
2024-09-24 | 개시 | Robert W. Baird | Outperform |
2024-09-18 | 다운그레이드 | Wolfe Research | Peer Perform → Underperform |
2024-09-04 | 다운그레이드 | Needham | Buy → Hold |
2024-06-25 | 다운그레이드 | Oppenheimer | Outperform → Perform |
2024-06-24 | 다운그레이드 | Citigroup | Buy → Neutral |
2024-02-06 | 재개 | KeyBanc Capital Markets | Overweight |
2023-10-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
2023-10-12 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
2023-10-09 | 업그레이드 | JP Morgan | Neutral → Overweight |
2023-09-29 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
2023-09-06 | 업그레이드 | Needham | Hold → Buy |
2023-09-05 | 다운그레이드 | UBS | Buy → Neutral |
2023-08-01 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
2023-05-23 | 개시 | UBS | Buy |
2023-04-14 | 개시 | Mizuho | Buy |
2023-01-17 | 업그레이드 | JP Morgan | Neutral → Overweight |
2022-10-28 | 다운그레이드 | Citigroup | Buy → Neutral |
2022-10-20 | 업그레이드 | BofA Securities | Neutral → Buy |
2022-10-12 | 개시 | Jefferies | Hold |
2022-09-08 | 업그레이드 | Citigroup | Neutral → Buy |
2022-08-15 | 다운그레이드 | CLSA | Buy → Outperform |
2022-08-12 | 다운그레이드 | Citigroup | Buy → Neutral |
2022-08-12 | 다운그레이드 | JP Morgan | Overweight → Neutral |
2022-08-12 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
2022-06-06 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
2022-04-06 | 개시 | Wolfe Research | Outperform |
2022-01-31 | 업그레이드 | Citigroup | Neutral → Buy |
2022-01-31 | 업그레이드 | Goldman | Neutral → Buy |
2022-01-28 | 업그레이드 | RBC Capital Mkts | Underperform → Sector Perform |
2022-01-24 | 업그레이드 | BofA Securities | Underperform → Neutral |
2022-01-24 | 업그레이드 | JP Morgan | Neutral → Overweight |
2022-01-13 | 업그레이드 | CLSA | Outperform → Buy |
2022-01-13 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
2021-12-21 | 업그레이드 | KeyBanc Capital Markets | Sector Weight → Overweight |
2021-12-06 | 업그레이드 | Macquarie | Neutral → Outperform |
2021-10-22 | 업그레이드 | CLSA | Underperform → Outperform |
2021-08-02 | 다운그레이드 | CLSA | Outperform → Sell |
2021-08-02 | 다운그레이드 | Needham | Buy → Hold |
2021-07-28 | 업그레이드 | Jefferies | Underperform → Hold |
2021-07-26 | 다운그레이드 | JP Morgan | Overweight → Neutral |
2021-07-14 | 개시 | RBC Capital Mkts | Underperform |
2021-06-28 | 다운그레이드 | Citigroup | Buy → Neutral |
2021-06-22 | 업그레이드 | Macquarie | Neutral → Outperform |
2021-06-22 | 개시 | Robert W. Baird | Neutral |
2021-06-21 | 재확인 | Needham | Buy |
2021-06-16 | 다운그레이드 | BofA Securities | Neutral → Underperform |
2021-06-09 | 업그레이드 | CLSA | Sell → Outperform |
2021-05-21 | 업그레이드 | JP Morgan | Neutral → Overweight |
2021-05-11 | 업그레이드 | Citigroup | Neutral → Buy |
2021-04-30 | 다운그레이드 | Citigroup | Buy → Neutral |
2021-03-16 | 업그레이드 | Needham | Hold → Buy |
2020-11-02 | 업그레이드 | UBS | Neutral → Buy |
2020-10-30 | 업그레이드 | JP Morgan | Underweight → Neutral |
2020-10-27 | 업그레이드 | BofA Securities | Underperform → Neutral |
2020-08-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
2020-06-17 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
2020-05-01 | 다운그레이드 | JP Morgan | Neutral → Underweight |
2020-05-01 | 업그레이드 | Oppenheimer | Perform → Outperform |
2020-02-18 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
2020-02-03 | 개시 | CLSA | Underperform |
2020-01-31 | 다운그레이드 | UBS | Buy → Neutral |
2020-01-10 | 개시 | Oppenheimer | Perform |
2019-11-22 | 개시 | KeyBanc Capital Markets | Sector Weight |
2019-07-29 | 업그레이드 | UBS | Neutral → Buy |
2019-07-16 | 다운그레이드 | UBS | Buy → Neutral |
2019-05-06 | 업그레이드 | UBS | Neutral → Buy |
2019-04-18 | 업그레이드 | JP Morgan | Underweight → Neutral |
2019-01-25 | 다운그레이드 | Goldman | Buy → Neutral |
2019-01-25 | 다운그레이드 | JP Morgan | Neutral → Underweight |
2018-10-26 | 업그레이드 | Credit Suisse | Neutral → Outperform |
2018-07-02 | 개시 | Goldman | Buy |
모두보기
Resmed Inc 주식(RMD)의 최신 뉴스
There's Reason For Concern Over ResMed Inc.'s (NYSE:RMD) Price - simplywall.st
Sleep Apnea Oral Appliances MarketGlobal Forecast to 2030 with SomnoMed, Resmed, ProSomnus, DynaFlex, Vivos Therapeutics, and OpenAirway Leading - Yahoo Finance
ResMed Inc. Files Conflict Minerals Disclosure Report for 2024 - TipRanks
Actigraphy Devices Market Report 2025-2034 | Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape - GlobeNewswire Inc.
ResMed CFO Executes Stock Transaction Under Rule 10b5-1 Plan - TipRanks
ResMed CFO Brett Sandercock sells $891,285 in stock By Investing.com - Investing.com South Africa
Hedge Fund and Insider Trading News: Bill Ackman, Paul Tudor Jones, Chase Coleman, John Paulson, Polus Capital Management, VFC Corp (VFC), ResMed Inc (RMD), and More - Insider Monkey
ResMed CFO Brett Sandercock sells $891,285 in stock - Investing.com Australia
ResMed’s SWOT analysis: sleep tech giant faces growth challenges, new markets - Investing.com
ResMed (RMD) Up 4% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Are Wall Street Analysts Bullish on ResMed Stock? - Inkl
Are Wall Street Analysts Bullish On ResMed Stock? - Barchart.com
Is it Worth Retaining ResMed Stock in Your Portfolio Now? - Nasdaq
Insider Sell: Witte De Sells 2,000 Shares of ResMed Inc (RMD) - GuruFocus
ResMed CFO Sells Shares - marketscreener.com
Why Kogan, Monash IVF, OFX, and ResMed shares are falling today - MSN
Down 5%: What's going on with the ResMed share price? - MSN
RMD ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of ResMed Inc. Shareholders Who Lost Money - ACCESS Newswire
Morgan Stanley sees ‘modest’ earnings impact to ResMed from Apnimed - Yahoo Finance
Should you buy the dip in the ResMed share price? - MSN
ResMed Draws Analyst Skepticism After Apnimed Announces Positive Results From Investigational Sleep Apnea Drug: Retail’s Unmoved By Stocktwits - Investing.com India
ResMed Draws Analyst Skepticism After Apnimed Announces Positive Results From Investigational Sleep Apnea Drug: Retail’s Unmoved - MSN
Positive Phase 3 Trial Results for RMD's Sleep Apnea Treatment | - GuruFocus
ResMed (RMD) Faces Potential Market Challenges from New Sleep Ap - GuruFocus
ResMed (RMD) Faces Potential Market Challenges from New Sleep Apnea Treatment | RMD Stock News - GuruFocus
Here's Why ResMed (RMD) is a Strong Growth Stock - Yahoo Finance
ResMed (NYSE:RMD) Seems To Use Debt Rather Sparingly - simplywall.st
Apnea Therapy Market Is Booming Worldwide 2025-2032 | ResMed Inc., Koninklijke Philips N.V. - openPR.com
Resmed (RMD) Partners with Rugby Tour to Promote Sleep Health | - GuruFocus
ResMed named Sleep Partner of the Qatar Airways British & Irish Lions Tour - TipRanks
Resmed Champions Sleep Health as The Official Sleep Partner of The Qatar Airways British & Irish Lions Tour to Australia 2025 - The Spec
Patient Monitoring Stocks Q1 Teardown: ResMed (NYSE:RMD) Vs The Rest - Yahoo Finance
Resmed Inc Updates Dividend Exchange Rate for CDI Holders - TipRanks
Levi & Korsinsky Reminds ResMed Investors of the Ongoing Investigation into Potential Violations of Securities LawsRMD - ACCESS Newswire
ResMed CEO Michael Farrell sells $1.95m in stock By Investing.com - Investing.com Canada
Resmed Insider Sold Shares Worth $1,948,003, According to a Recent SEC Filing - marketscreener.com
ResMed CEO Michael Farrell sells $1.95m in stock - Investing.com
Insider Sell: Peter Farrell Sells 2,000 Shares of ResMed Inc (RMD) - GuruFocus
Resmed prevails over Cleveland Medical in CPAP patent review - BioWorld MedTech
Is ResMed Inc.'s (NYSE:RMD) Latest Stock Performance A Reflection Of Its Financial Health? - simplywall.st
Ex-Dividend Reminder: Seaboard, KB Home and ResMed - Nasdaq
ResMed Inc Reports Changes in CDIs and Securities for April 2025 - TipRanks
Jim Cramer on Viemed Healthcare (VMD): “Interesting, But I’m a ResMed Guy” - Yahoo Finance
ResMed Wins Invalidation of Sleep Apnea Tech Patent After Remand - Bloomberg Law News
Is It Smart To Buy ResMed Inc. (NYSE:RMD) Before It Goes Ex-Dividend? - Yahoo Finance
ResMed Corporation: GLP-1 Demand Generation Strategy to Expand Customer Base & Strengthen Their Position! - Smartkarma
Intuitive wins new FDA nod for single port robot; Resmed buys diagnostic facility - MedTech Dive
Resmed Inc (RMD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):